0TB Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0TB from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Theravance Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.60 |
| 52 Week High | US$9.90 |
| 52 Week Low | US$7.00 |
| Beta | 0.22 |
| 1 Month Change | 1.18% |
| 3 Month Change | -6.01% |
| 1 Year Change | 10.26% |
| 3 Year Change | -0.58% |
| 5 Year Change | -62.61% |
| Change since IPO | -55.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0TB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -3.6% | 2.1% |
| 1Y | 10.3% | -15.9% | 16.5% |
Return vs Industry: 0TB exceeded the German Pharmaceuticals industry which returned -14.6% over the past year.
Return vs Market: 0TB underperformed the German Market which returned 16.7% over the past year.
Price Volatility
| 0TB volatility | |
|---|---|
| 0TB Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0TB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0TB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 99 | Rick Winningham | www.theravance.com |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
Theravance Biopharma, Inc. Fundamentals Summary
| 0TB fundamental statistics | |
|---|---|
| Market cap | €427.69m |
| Earnings (TTM) | -€47.53m |
| Revenue (TTM) | €60.80m |
7.3x
P/S Ratio-9.3x
P/E RatioIs 0TB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0TB income statement (TTM) | |
|---|---|
| Revenue | US$63.19m |
| Cost of Revenue | US$36.50m |
| Gross Profit | US$26.69m |
| Other Expenses | US$76.09m |
| Earnings | -US$49.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 42.23% |
| Net Profit Margin | -78.18% |
| Debt/Equity Ratio | 0% |
How did 0TB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/12 15:11 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Theravance Biopharma, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Tazeen Ahmad | BofA Global Research |
| Julian Harrison | BTIG |